The overall goal of this project is to improve the survival and quality of life of patients with pancreatic and biliary tract carcinoma using photodynamic therapy (PDT). This clinical project involves a number of phase I and III studies using two different photosensitizers (PS), and derives from experimental and early clinical studies of PDT in pancreatic and biliary tract malignancies by our group. In addition, new means for non- invasively measuring PS concentrations and light transmission within tissue will be usedto provide monitoring information that could ultimately be used to manipulate PDT in real time and produce a more effective and uniform therapeutic outcome. The overall theme of the hypotheses tested here is that a reduction in tumor burden can be achieved safely with PDT, and will lead to improvements in survival and quality of life of patients with pancreatic and biliary tract cancer.
In Aim 1, following on from our recently completed phase II study of porfimer sodium PDT in biliary tract carcinoma (ETC), a phase III study of palliative PDT plus stenting vs. stenting alone will be performed in patients with locally advanced or metastatic BTC.
Aim 2 will test the feasibility and safety of neoadjuvant PDT using porfimer sodium in patients undergoing attempted curative surgical resection of proximal biliary tract carcinoma, with the goal of improving RO resection rates and overall survival. Accurate techniques for dosimetry with photosensitizer and structural treatment planning will also be developed, with the aims of improving PDT dose accuracy and prediction of effect in biliary tract cancer.
In Aim 3, in a standard phase I/II dose ranging study using a single fiber followed by a non-randomized phase II multiple fiber study, verteporfin PDT will be administered to patients with locally advanced pancreatic carcinoma to identify the treatment parameters with which to achieve safe and effective tumor necrosis. The results of this study will then be used to inform Aim 4, a randomized phase ll/lll study of verteporfin PDT + standard chemotherapy vs. chemotherapy alone for locally advanced pancreatic cancer. This latter trial will involve full light dose treatment planning with implantation of multiple diffusing fibers into the prescribed volume. The completion of these aims will test the clinical hypotheses that PDT can be successfully incorporated into pancreatobiliary cancer management as a combination approach, either adjuvant or neoadjuvant. Potential benefits to public health: this study with 4 clinical trials could provide new treatments for two cancers, PanCa and BTCwhich currently have few treatment options and are usually fatal putting a heavy burden on society in terms of cost and suffering.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA084203-10
Application #
8403909
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
10
Fiscal Year
2013
Total Cost
$201,264
Indirect Cost
$44,671
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Huang, Huang-Chiao; Mallidi, Srivalleesha; Liu, Joyce et al. (2016) Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer Res 76:1066-77
Tangutoori, Shifalika; Spring, Bryan Q; Mai, Zhiming et al. (2016) Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer. Nanomedicine 12:223-34
Obaid, Girgis; Broekgaarden, Mans; Bulin, Anne-Laure et al. (2016) Photonanomedicine: a convergence of photodynamic therapy and nanotechnology. Nanoscale 8:12471-503
Pogue, Brian W; Paulsen, Keith D; Samkoe, Kimberley S et al. (2016) Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention. Med Phys 43:3143
Pogue, Brian W; Elliott, Jonathan T; Kanick, Stephen C et al. (2016) Revisiting photodynamic therapy dosimetry: reductionist & surrogate approaches to facilitate clinical success. Phys Med Biol 61:R57-89
Huggett, Matthew T; Tudzarova, Slavica; Proctor, Ian et al. (2016) Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Oncotarget 7:18495-507
Spring, Bryan Q; Bryan Sears, R; Zheng, Lei Zak et al. (2016) A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. Nat Nanotechnol 11:378-87
de Souza, Ana Luiza Ribeiro; Marra, Kayla; Gunn, Jason et al. (2016) Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer. Br J Cancer 115:805-13
Mohammad, Goran Hamid; Olde Damink, S W M; Malago, Massimo et al. (2016) Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome. PLoS One 11:e0151635
Mallidi, Srivalleesha; Mai, Zhiming; Rizvi, Imran et al. (2015) In vivo evaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints. J Biomed Opt 20:048003

Showing the most recent 10 out of 150 publications